Faced with these hurdles to gain global market access in the constantly shifting healthcare landscape?
- Inconsistent reimbursement policies and processes across geographies
- Lack of consistently maintained, integrated information resources
- Expensive and time-consuming country market research requiring multiple resources to procure data that may not be current
- Increasing use of MEAs significantly impacting pricing and reimbursement negotiations
GMAS provides on-demand access to DRG’s expertly curated Global Market Access datasets, country benchmarking tools, commercially focused country-specific analysis on 29 counties, and the first managed entry agreement (MEA) global database.
Continuously updated by country market experts as new data emerges, GMAS allows users to gain a clear understanding of the complex and evolving drivers and barriers to successful global market access by staying abreast of market shifts, key decision-makers, and trends that affect the market access landscape.
GMAS equips biopharma teams with critical insights to:
- Gain a comprehensive understanding of specific country markets
- Answer questions on market entry, barriers, go-to-market strategies, and payer messaging via a country or indication lens
- Benchmark relevant market access factors including healthcare spending, pharmaceutical market, use of HTA, ease of price setting, and intellectual property freedom between countries
- Prioritize markets that provide the most favorable conditions for commercialization
- Calibrate strategic assumptions with comprehensive, country-specific analysis before committing resources
Four integrated sections provide a detailed deep-dive comparative country analysis, including healthcare systems and processes/details for market authorization, pricing, reimbursement, pharmacoeconomic analysis, and cost-containment strategies.
Geographic Focus – Country summaries and analysis to build country-specific effective market access plans.
Therapeutic Focus – Epidemiology, mortality, and global burden of disease data to identify market opportunities.
Commercial Attractiveness – Proprietary tools for comparative benchmarking to mitigate risk and prioritize assets.
Insights Library – Rich, expertly curated knowledge-sharing documents to explore given markets.
MEAs are reshaping the contracting landscape. Now the industry’s only global MEA database with qualitative insights empowers users with the critical intelligence necessary to map out an effective strategy to secure favorable reimbursement.
The GMAS MEA database enables all users to:
- Review collated contract information between pharma companies and payers around the world
- Identify what contracts currently exist for specific products
- Uncover which companies are leveraging financial and outcomes-based contracts
- Prioritize market-specific product strategies or propose risk-benefit schemes to increase chances of successful pricing and reimbursement of new products
- Examine how aggressive countries are in terms of risk-based contracts
- Find out which indications are most associated with certain types of contracts
- Benefit from lessons learned with agreements for specific indications and geographies
DRG creates enduring working relationships with a focus on collaboration and thought partnership to facilitate our clients’ pursuit of global market access. With a bench of commercially focused analysts and thought leaders—and an industry-leading Client Experience (CE) team—GMAS enables clients to easily:
- Incorporate expert insight into the most critical market access decisions—and everyday workflow
- Save time and headcount with tools, data, and insight tailored to global market access needs